Spinal muscular atrophy in Brazil: from individual treatment to global management

This publication has 16 references indexed in Scilit:

• Clinicogenetic characterization and response to disease-modifying therapies in spinal muscular atrophy: real-world experience from a reference center in Southern Brazil
  Jornal de Pediatria, 2024
• Newborn Screening and Presymptomatic Treatment of Metachromatic Leukodystrophy
  New England Journal of Medicine, 2024
• Judicialização do Zolgensma no Ministério da Saúde: custos e perfil clínico dos pacientes
  Revista de Saúde Pública, 2024
• Cost-effectiveness of spinal muscular atrophy newborn screening based on real-world data in Belgium
  Neuromuscular Disorders, 2023
• Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening—A Systematic Review
  Genes, 2023
• Neonatal screening for spinal muscular atrophy: A pilot study in Brazil
  Genetics and Molecular Biology, 2023
• Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening
  Developmental Medicine & Child Neurology, 2022
• Therapies in preclinical and clinical development for Angelman syndrome
  Expert Opinion on Investigational Drugs, 2021
• Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments
  Orphanet Journal of Rare Diseases, 2021
• Intragenic variants in the SMN1 gene determine the clinical phenotype in 5q spinal muscular atrophy
  Neurology Genetics, 2020